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Abstract: Hemophilia A is a rare inherited bleeding disorder due to mutation of the gene that 
encodes the coagulation protein factor VIII. Historically, prior to the availability of treatment 
with factor VIII preparations, most boys died from uncontrolled bleeding, either spontaneous 
bleeding or after injury, before reaching 20 years of age. One of the most impressive triumphs 
of modern medicine is that with current recombinant factor VIII replacement therapy, a boy 
born in the 21st century with severe hemophilia A can anticipate a normal life expectancy with 
essentially no permanent complications from bleeding. For severe hemophilia A, current optimal 
treatment should have two goals: first, to provide sufficient factor VIII to prevent spontaneous 
bleeding, and second, to provide sufficient factor VIII to have normal coagulation function after 
any trauma. However, the replacement therapy requires tremendous resources for effective use, 
and remains extraordinarily expensive. Thus there are opportunities for further advances in 
therapy for hemophilia A. Two major concerns continue to trouble current optimal treatment 
approaches: some patients will develop neutralizing antibodies during the first 50 infusions of 
therapeutic factor VIII, and second, to administer therapeutic factor VIII every other day in 
young boys often requires placement of a central venous access device, and such use carries 
the life-threatening risks of infection and thrombosis. Because of the effectiveness of current 
therapy, any new developments in treatment will require significant concerns for safety, both 
immediate and in the long term. A number of research groups seek to prolong the biological 
efficacy of infused recombinant factor VIII. Currently, one such promising development is in 
the advanced stages of clinical trial. The goals will be to improve further the quality of life of 
an individual with severe hemophilia A, and to reduce the burden of current treatment strategies 
on families and medical resources. Hopefully, the hemophilia community will continue to 
participate actively in the clinical trials needed to address these new challenges.
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Introduction
Hemophilia A is a rare inherited bleeding disorder due to mutation of the gene that 
encodes the coagulation protein factor VIII. Severe hemophilia A is a condition 
almost exclusively found in males as the gene is located on the X chromosome; the 
incidence of hemophilia A is approximately 1 in 5000 male births. Approximately half 
of the sons of carrier females are affected, but more than 50% of the boys born with 
severe hemophilia A have no family history to suggest the need for carrier testing.1,2 
Historically, prior to the availability of treatment with factor VIII preparations, most 
boys died from uncontrolled bleeding, either spontaneous bleeding or after injury, 
before reaching 20 years of age.3 Those who survived suffered from the complications Therapeutics and Clinical Risk Management 2009:5 392
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of frequent bleeding, primarily severe and incapacitating 
damage involving their weight bearing joints. Intracranial 
hemorrhage occurred with an incidence of approximately one 
in 200 per year, often with severe permanent brain damage 
in the boys that survived the initial bleeding episode.4 One 
of the most impressive triumphs of modern medicine is that 
with current recombinant factor VIII replacement therapy, 
a boy born in the 21st century with severe hemophilia A 
can anticipate a normal life expectancy with essentially 
no permanent complications from bleeding.5 However, 
the replacement therapy requires tremendous resources for 
effective use, and remains extraordinarily expensive.6 Thus 
there are opportunities for further advances in therapy for 
hemophilia A.
Historical developments 
in hemophilia   A: up to 2008
In 1960 the average life expectancy for severe hemophilia A 
was less than 20 years, and the quality of life was generally 
devastating from joint bleeding complications or intracra-
nial hemorrhage.7,8 The severity of hemophilia A depends 
primarily on the concentration of factor VIII activity in 
the blood, and is divided based on clinical phenotype into 
severe (1% of normal circulating factor VIII activity), 
moderate (1%–4%), and mild (5%–25%). The work of Judith 
Graham Poole and others led to fractionation of blood, the 
serendipitous discovery of cryoprecipitate, and eventually 
to the use of plasma-derived preparations of factor VIII. 
Through improvements in the preparation of these plasma-
derived products, and efforts to increase availability, there 
was sufficient supply of factor VIII preparations so that most 
boys with severe hemophilia A were treated when sponta-
neous or traumatic bleeding episodes occurred, a style of 
therapy termed “on-demand” treatment, as factor VIII was 
administered to treat bleeding after it had already started, 
rather than therapy to prevent bleeding at all. With vigorous 
medical support primarily through hemophilia treatment 
centers and home treatment programs, and with plasma-
derived factor VIII products widely available, the death 
rate for hemophilia A had improved dramatically by the late 
1970s. In a recent prospective study, it was found that patients 
with severe hemophilia who attended clinic at hemophilia 
treatment centers in the US experienced 40% less mortality 
than patients who did not visit hemophilia treatment centers, 
reflecting the need for comprehensive expertise and resources 
in treating this disorder.9 Such successful comprehensive 
treatment centers are being developed around the world.10 
Joint damage was much less in most boys, but still severe, 
resulting in marked compromise in their quality of life.11 
However, spontaneous intracranial hemorrhage remained a 
significant morbidity even in aggressive on demand treatment 
programs, with neonatal hemorrhage a particular manage-
ment problem even in known female carriers.12,13
Then in the early 1980s, the epidemic of HIV devastated 
the hemophilia community, and by 1985 nearly 75% of 
the severe hemophilia A patients in the US had acquired 
HIV. Also, many of the moderate and mild hemophilia A 
patients, who used factor VIII only occasionally, were also 
infected. The ironic tragedy was that the source of the HIV 
infection was the plasma-derived factor VIII products that 
had promised to be life-saving. The virus had entered the 
blood supply, was carried into the plasma preparations, and 
proved to be highly contagious for the patients with severe 
hemophilia A when they received plasma preparations for 
bleeding episodes as often as twice a week. More than half 
of these infected individuals died from HIV by 1995, when 
effective treatment for HIV infection first became widely 
available.11
Amidst the confusion and anger during the early years 
of the HIV epidemic, the response of a significant number 
of individuals with hemophilia A was to stop taking any 
plasma-derived products completely, preferring to return 
to the clinical situation of 1960, with the consequences of 
severe bleeding poorly treated.
As the community dealt with the horrors of HIV, a second 
epidemic gradually became apparent. Over 95% of severe 
hemophilia A patients had also acquired hepatitis C infection 
through plasma-derived preparations of factor VIII.14 There 
were several reasons that realization of the severity of the 
epidemic of hepatitis C developed slowly in the hemophilia 
community. Most medical attention was concentrated on 
dealing with the HIV epidemic, a much more rapid and 
devastating illness. Hepatitis C virus was not identified until 
1989. Infection with hepatitis C rarely causes acute illness, 
is eliminated by the immune system approximately 20% of 
the time, often remains completely asymptomatic, and, when 
symptomatic, becomes a chronic medical problem, often 
minimally symptomatic for years until manifesting primarily 
as liver damage worsening over years, with cirrhosis and liver 
failure apparent 10 to 20 years later, or liver cancer apparent 
20 to 30 years after infection. Thus, for patients with severe 
hemophilia A infected by plasma-derived preparations in 
the late 1970s and early 1980s, these complications became 
widely apparent only in the late 1990s.
Fortunately, for individuals with hemophilia A, four 
independent developments have occurred over the past Therapeutics and Clinical Risk Management 2009:5 393
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20 years that have improved their clinical situation again. 
These developments support optimistic predictions of normal 
life expectancy for boys born with hemophilia A in the 21st 
century, and for effective treatments for older individuals 
who have acquired the twin infections of HIV and hepatitis C. 
First, effective treatments have been developed for HIV 
infection. Many of the patients with hemophilia A infected 
initially in the early 1980s have had their HIV infection 
converted to a chronic manageable condition that, while 
not cured, allows them to live a relatively normal life again. 
Second, treatments that provide cure for significant numbers 
of individuals infected with hepatitis C have been developed 
and new promising treatments are developing relatively 
rapidly. Current treatment for hepatitis C is arduous, but 
cure rates of up to 40% have been reported in hemophilia A 
patients.
Two other developments have been critical for hemophilia 
A treatment. Preparations of the plasma-derived products 
have been improved: steps have been added to test donor 
populations that provide plasma for purification of factor VIII, 
steps have been added to inactivate any viruses present, 
and additional steps of factor VIII purification have been 
included. The success of these efforts is demonstrated by 
the fact that no transmission of HIV, hepatitis C, or other 
virus has been documented to be associated with any of these 
modern plasma-derived factor VIII preparations since 1990. 
This safety record for these products ranks among the best 
for any pharmaceutical product.15–18
The fourth major development for hemophilia A over 
the past 20 years has been the provision of recombinant 
factor VIII, widely available shortly after completion of 
the clinical trials in 1994. Several preparations of recom-
binant factor VIII are currently available for patients with 
hemophilia A. The World Federation of Hemophilia provides 
a summary listing of all currently available factor VIII 
products and their major characteristics; the latest update is 
edition 8 (April 2008).19 The development of recombinant 
factor VIII has been a major step forward in the treatment of 
hemophilia A.20 There is not consensus regarding whether 
any one of the currently available recombinant factor VIII 
products has significant clinical advantages over the others 
in any particular clinical setting. Each product has a strong 
safety record, has been available for a number of years, 
and is licensed in many countries. Each of the products 
has its proponents; randomized clinical trials comparing 
these products are unlikely. Potential improvements for 
recombinant factor VIII include advances that would allow 
prevention of spontaneous bleeding with fewer intravenous 
infusions. Besides the obvious convenience to the patient of 
fewer infusions required to prevent spontaneous bleeding, 
there are medical advantages as well. The current rate of 
septic arthritis in males with hemophilia is approximately 
83 per 100,00 person-years compared with only 2 to 6 per 
100,000 person-years in non-hemophilia.21 Central venous 
access device use and infection with hepatitis C or HIV were 
not risk factors for septic arthritis in this study; presumably 
the risk factor was related to multiple intravenous infusions. 
Advances in the effective half life of recombinant factor VIII 
would be expected to reduce the incidence of septic arthritis 
in hemophilia.
The history of hemophilia A treatment over the past 
40 years has been tumultuous: with two major epidemics in 
the 1980s, but ending with the availability of recombinant 
factor VIII, and current expectations of essentially normal life 
expectancy for this previously devastating genetic disease. 
Most of the hemophilia community probably views this past 
40 years as a story of survival, and with relief, rather than a 
story of triumph. Perhaps with more years to provide greater 
historical perspective, the tragedies of epidemics will fade 
and the scientific triumph of recombinant factor VIII will 
become the dominant story, along with the change in life 
expectancy for severe hemophilia A boys from less than 
20 years to normal life expectancy, achieved in less than 
30 years of medical progress.
Current treatment for hemophilia A
For severe hemophilia A, current optimal treatment should 
have two goals: first, to provide sufficient factor VIII to prevent 
spontaneous bleeding, and second, to provide sufficient factor 
VIII to have normal coagulation function after any trauma. 
At the present time, optimal treatment so defined requires 
much medical support and family support, primarily due to 
the relatively short half-life of infused factor VIII, approxi-
mately 10 hours. Until more effective treatment alternatives 
are available, optimal treatment as defined here both requires 
tremendous effort and is extraordinarily expensive, and thus 
often requires any of a number of compromises that lead to 
adequate, but sub-optimal, therapy.
Factor VIII requires intravenous infusion, and is bound 
rapidly to its carrier molecule von Willebrand protein. 
Without effective interaction with von Willebrand protein, 
the infused factor VIII disappears rapidly in minutes due 
to degradation by plasma proteases, as occurs in the sub-
type of von Willebrand Disease, Type N (for Normandy, 
where it was first described), in which the protein domain 
of von Willebrand protein that interacts with factor VIII Therapeutics and Clinical Risk Management 2009:5 394
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is rendered ineffective by mutations. With a half-life of 
10 hours, intravenous infusion of factor VIII is required 
approximately every other day to maintain factor VIII 
concentrations high enough to provide adequate support for 
coagulation to prevent spontaneous bleeding. The therapeutic 
goal is to achieve a clinical situation that is roughly similar 
to individuals with moderate hemophilia A in whom the 
concentration of factor VIII activity is more than 2% by stan-
dard clotting assays. These boys with moderate hemophilia A 
rarely experience spontaneous bleeding, although traumatic 
bleeding remains problematic. Thus, the assumption initially 
was that maintenance of factor VIII activity greater than 2% 
would be necessary to prevent any spontaneous bleeding 
episodes. However, numerous studies over the past 20 years 
have demonstrated that while clotting assays are pretty 
accurate in predicting the clinical phenotype of individuals 
with hemophilia A, there is significant variation that is much 
more difficult to predict, again confirming that coagulation 
is indeed a complex problem. Many proteins need to inter-
act to provide effective coagulation and protection against 
spontaneous bleeding, and many boys do not need intrave-
nous infusion of factor VIII as often as every other day to 
be protected from spontaneous bleeding episodes. In this 
population, the clotting assays do not correlate as closely as 
needed with protection from spontaneous bleeding. Proper 
understanding of the clinical situation and some means to 
identify which boys will need every other day infusions are 
critical because currently such a rigorous infusion schedule 
often requires the placement of a central venous access 
device with attendant risks for medical complications.22 
These complications could be avoided by predicting which 
boys do not require such frequent infusions.
In severe hemophilia A, spontaneous bleeding will occur 
in some boys during the third day after infusion of factor VIII. 
After several months, with many such “third days” with factor 
VIII concentrations less than 2%, most boys will experience 
spontaneous bleeding. However, some boys essentially never 
bleed spontaneously despite factor VIII levels of less than 
2% for many days, allowing these boys to receive infu-
sions only once each week to protect them from spontane-
ous bleeding.23,24 These considerations have led Canadian 
investigators to advocate a graduated response to treatment 
for severe hemophilia A, in which recombinant factor VIII 
is infused once each week until the boy experiences unac-
ceptable spontaneous bleeding, at which time infusions are 
escalated to twice each week. Then in these boys, further 
spontaneous bleeding would lead to further escalation of 
infusions to 3 times per week, and then to every other day 
if necessary. Their initial encouraging experience with this 
approach has been published, and indeed, such an approach 
avoids the use of central venous access devices in many boys, 
avoiding the medical risks of such catheters.25,26
The major concern in this graduated escalation approach 
for infusions of factor VIII to prevent spontaneous bleeding 
is that many boys will experience spontaneous bleeding, 
raising the critical questions of how much spontaneous 
bleeding can occur in any single joint and how much joint 
damage can be sustained before the joint suffers irreversible 
damage.27 In one study delayed starting of prophylaxis until 
after several joint bleeds led to progression of arthropathy 
and deterioration of joint function over time.28 The subsidiary 
clinical question is then how much damage can the joint 
sustain before it significantly compromises the quality of 
life of the individual with severe hemophilia. One of the 
major advances now happening in the hemophilia commu-
nity in the 21st century is the gradual realization that these 
more subtle questions affecting hemophilia outcomes will 
be answerable only through properly conducted prospective 
clinical trials that compare different therapeutic approaches.29 
One of the first major prospective clinical trials addressing 
these questions was recently published.30 This trial compared 
prophylactic infusions in young children to prevent any 
spontaneous bleeding versus on-demand treatment infu-
sions with recombinant factor VIII. The regular prophylactic 
infusion schedule led to reduced spontaneous bleeding and 
much less joint damage. In addition, joints suffering only one 
or two spontaneous bleeding episodes had detectable joint 
damage several years later, suggesting that the joint damage 
may indeed be permanent, and perhaps progressive, once the 
process has been initiated by bleeding.
The above discussion considered only spontaneous 
joint bleeding, but similar results are typical for spontane-
ous intracranial hemorrhage in severe hemophilia patients: 
those on every other day full prophylaxis, with the target 
goal being factor VIII activity nadirs greater than 1%, very 
rarely experience intrancranial bleeding, while those patients 
using on-demand therapy continue to experience spontaneous 
intracranial bleeding and neurological sequelae.31,32 Whether 
gradually escalating schedules of factor VIII infusions risk 
intracranial bleeding is not clear yet.
Numerous questions remain to be addressed in future 
clinical studies. During the development of recombinant 
factor VIII, randomized prospective trials were not needed 
to demonstrate efficacy, primarily because the differences 
between no treatment and factor VIII infusion were dramatic, 
and there is an excellent correlation between clinical phenotype Therapeutics and Clinical Risk Management 2009:5 395
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for bleeding risk and the coagulation laboratory test of 
factor VIII activity. Now, however, the differences in out-
comes between different approaches of therapy with factor 
VIII preparations are much more subtle, and the answers to 
support evidence based clinical decisions will depend on 
randomized prospective clinical trials.33 In this context, it is 
hoped that more and more hemophilia A patients and their 
treating doctors will demand that the hemophilia community 
answer these questions through randomized studies, rather 
than through competing expert opinions or through political 
decisions that allocate limited resources. For example, is the 
quality of life of adult hemophilia A patients better using the 
graduated escalating frequency of infusions to prevent most 
spontaneous bleeding or using the regular infusion schedule 
of every other day to prevent essentially all spontaneous 
bleeding?34,35 Do the medical complications outweigh the 
benefits?36,37 What additional therapies are beneficial when 
treating the complications of severe hemophilia A?38–41 
Comparison data from clinical trials will be important to 
guide appropriate decisions for where and how society should 
allocate its health care resources.42
Even with recombinant factor VIII there is significant 
variability in the pharmacokinetic profiles between individu-
als with severe hemophilia A, as significant as previously 
experienced with plasma-derived factor VIII preparations. 
Anecdotal experience indicates also that some patients will 
have improved half life for infused therapeutic factor VIII 
with one product over another, but this observation has not 
been rigorously tested in randomized clinical trials. There-
fore it is difficult to predict which products will benefit 
one patient more than another product, or even whether 
switching products will provide benefit in any individual 
patient.43 Variables that influence the pharmacokinetic profile 
in individual patients need additional study,44 but appear to 
include variation in surface receptors that affect factor VIII 
binding and metabolism.45
Prevention of spontaneous bleeding episodes is an impor-
tant goal in hemophilia care. Another important consideration 
will be how to treat optimally for minor traumatic bleeding. 
Spontaneous bleeding is rare in boys with factor VIII activity 
of more than 2%. However, in active boys, of course, minor 
traumatic bleeding often occurs in the presence of higher 
concentrations of factor VIII. Do these traumatic bleeds 
cause the same risks for permanent joint damage as spon-
taneous bleeding? Are there better tests, either genetic or 
biochemical laboratory tests, that may define populations of 
boys at greater risk for damage from minor traumatic bleeds? 
And, are there programs for clinical management that lead to 
better outcomes for these growing boys?46 Since coagulation 
is the result of complex interactions involving over a dozen 
proteins, and each of those proteins has biological differ-
ences, the clinical situation in hemophilia A is quite variable, 
and bleeding frequencies do not reflect solely the activity 
obtained from factor VIII laboratory testing.47 There is a signi-
ficant need for new coagulation tests that allow prediction 
of which boys would benefit from the different approaches 
to treatment of their severe hemophilia A.
Complications of current treatment 
of hemophilia A
Two major concerns continue to trouble current optimal 
treatment approaches for severe hemophilia A. First, some 
patients will develop inhibitors (antibodies that neutralize the 
activity of the FVIII molecule) during the first 50 infusions 
of therapeutic factor VIII. Second, to administer therapeutic 
factor VIII every other day in young boys often requires 
placement of a central venous access device, and such use 
carries the risks of infection and thrombosis, either of which 
complication may be life-threatening. Much effort is directed 
currently at understanding which boys are at risk for inhibi-
tors, and which are at risk for complications of central venous 
access devices.
The incidence of neutralizing inhibitor formation varies 
depending on the population studied, but generally the inci-
dence of inhibitor formation is 15% to 20%.48 Since most indi-
viduals with severe hemophilia A are missing large portions, 
if not all, of the factor VIII protein, the immune systems in 
these individuals would be expected to perceive the epitopes 
of the missing factor VIII molecule as “foreign” and trigger 
an immune response against those foreign epitopes.49,50 From 
this perspective, then, it is surprising that therapeutic infu-
sions with factor VIII do not trigger formation of neutralizing 
inhibitors in most of the recipients with severe hemophilia A. 
Perhaps the factor VIII molecule lacks immunogenicity 
in many individuals due to sequence similarity with other 
proteins such as factor V, but the reasons for only a small 
proportion of patients developing neutralizing antibodies are 
not well understood. With continued infusion of factor VIII 
to induce a form of immune tolerance, some of these inhibi-
tors disappear, the half-life of infused factor VIII becomes 
again normal, and these individuals can be treated again as 
other patients with severe hemophilia A. With addition of 
immune-modulatory therapy along with continued infusions 
of factor VIII, a few more of these neutralizing inhibitors dis-
appear. The remaining individuals, approximately 5% to 8% 
of severe hemophilia patients, are treated with NovoSeven® Therapeutics and Clinical Risk Management 2009:5 396
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(Novo Norkisk), a preparation of activated factor VII, and/or 
FEIBA (Factor VIII Inhibitor Bypassing Activity), a plasma-
derived preparation of coagulation factors that has been 
partially activated during the preparation process.51,52 It is 
encouraging that the use of these products to treat hemophilia 
patients with inhibitors is guided by results from randomized 
clinical trials.29 The half-life of each of these preparations 
is much shorter than factor VIII, leaving these inhibitor 
patients with a higher frequency of spontaneous bleeding. 
Treatment of trauma and coagulation support for surgery is 
essentially as effective with these alternative preparations 
in inhibitor patients as factor VIII preparations in patients 
without inhibitors.53
A major question in modern therapy for hemophilia 
revolves around how to predict which boys with severe hemo-
philia A will develop inhibitors. Younger siblings of boys 
who have developed high titers of neutralizing inhibitors, 
are at markedly increased risk of inhibitor development, 
suggesting that individual immune systems account for some 
of the variation in inhibitor development. Genetic analyses of 
the individual gene defects for hemophilia A are beginning 
to help provide additional understanding.54 As would be 
expected, absence of large portions of the gene, or mutations 
that lead to absence of large portions of the protein correlate 
well with higher risks of inhibitor development, presumably 
because the immune system senses the infused therapeutic 
factor VIII as a foreign protein, since most T-cell and B-cell 
epitopes of factor VIII are absent in these boys with large 
deletions of protein. Other mutations in factor VIII may create 
novel epitopes in the endogenously produced FVIII, so that 
the individual immune systems sense these regions of the 
infused therapeutic FVIII as antigenic to varying degrees. 
Differences in epitope profile may also correlate with the 
success of immune tolerance induction after the development 
of a high titer inhibitor to factor VIII. Such differences in 
B-cell epitopes, for example, in the FVIII C2 and A2 domains 
may be associated with failure to achieve immune tolerance 
induction with current approaches. Inclusion of the carrier 
molecule for FVIII, von Willebrand protein, may somehow 
modulate the immune recognition of these B-cell epitopes.55,56 
Continuing research will expand the data bases of genetic 
differences underlying hemophilia A, and how these genetic 
differences correlate with risks for inhibitor development, 
and with the response to immune tolerance induction.57
In addition to genetic variables in mutations of the 
factor VIII molecule and in the immune system, environmental 
variables may be important also. Interpretations of the clinical 
data in this area of inhibitor formation are controversial and 
more studies should help clarify the significant risk factors 
for inhibitor formation. Currently, some studies suggest 
that young children exposed to factor VIII in the setting of 
activated immune reactions, as in infections and/or during and 
after surgery, may have higher risk of developing inhibitors. 
Other studies support the concern that recombinant factor 
VIII is associated with higher risk of inhibitor formation.58,59 
Some of these studies support the hypothesis for a mecha-
nism of inhibitor formation due to the more highly purified 
factor VIII protein in the recombinant preparations.60 Other 
interpretations suggest that the association of the natural 
carrier protein, von Willebrand protein, with the infused 
therapeutic factor VIII provides some undefined mechanism 
that decreases the formation of inhibitors.61,62 Inhibitor devel-
opment is a poorly understood phenomenon, and there are few 
randomized clinical trials. A list of putative environmental 
factors that may influence inhibitor development includes: 
1) is the age of first exposure critical, 2) is higher dosing 
more important as an independent risk factor at young ages, 
3) is the setting of first use of factor VIII infusion critical to 
triggering the immune response of inhibitor development, 
that is, in the setting of activation of the immune system 
after surgery, infection or trauma critical for increased risk of 
inhibitor development, 4) is the presence of the carrier protein 
von Willebrand factor in the infused factor VIII preparation 
critical for protection against inhibitor development.63 Then, 
complicating the interpretation of anecdotal data from small 
numbers of patients who develop inhibitors is whether the 
answers regarding environmental contributions are different 
depending on the individual genetic mutations that cause 
hemophilia A.
In such situations when facing many questions about 
what therapy is associated with better outcomes, other areas 
of medicine have used prospective randomized clinical 
trials to compare the therapeutic options. Several hurdles 
to this approach complicate use of randomized trials in the 
hemophilia community. Perhaps most important among 
these barriers is the emotional reluctance of both families 
and hemophilia physicians to “subjecting” young boys to 
randomization of the choice of factor VIII preparations. This 
reluctance is understandable in view of the past history of 
two life-threatening epidemics transmitted to patients with 
hemophilia through plasma-derived factor VIII preparations. 
However, as there has been no transmission of any significant 
virus through plasma-derived products since 1990, the reas-
surance of this extensive experience is beginning to balance 
the fear of transmission of a new virus. Conversely, there 
are some hemophilia physicians who advocate using only Therapeutics and Clinical Risk Management 2009:5 397
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von Willebrand protein containing factor VIII preparations 
in view of the evidence suggesting that the rate of inhibitor 
development is lower with these preparations than with 
recombinant factor VIII.59 Currently, this decision requires 
using plasma-derived factor VIII preparations. Until the 
hemophilia community achieves some consensus on how 
to address this issue, randomized trials are unlikely to start. 
Fortunately, research in new factor VIII preparations may 
allow a third alternative to avoid this dilemma. If the fear 
is the potential danger of plasma-derived products, and the 
advantage is using von Willebrand protein containing prepa-
rations, then the third alternative is to prepare recombinant 
von Willebrand protein to infuse along with recombinant 
factor VIII. Several pharmaceutical companies are pursuing 
research aimed at providing such a preparation.
The second major concern troubling current treatment 
of hemophilia A involves the complications from use of 
central venous access devices to administer factor VIII every 
other day. The incidence of these complications, primarily 
infections and thromboses, varies considerably, depending 
on the population involved, on the experience and expertise 
of the hemophilia treatment center, and on the efforts of 
the families involved in home infusion for each individual 
child with severe hemophilia A. Some apparent conclusions 
emerge from most studies of the complications of use of such 
catheters. First, the complication rate is highest in children 
under 2 years of age, and yet, these are the individuals in 
whom venous access every other day is most problematic. 
Second, experience and training of the primary care provider 
in the home setting is critical to avoiding complications of 
catheter use. Third, there appear to be some boys in whom 
risks of complications are high for reasons not easily identi-
fied; some boys repeatedly acquire infections or thromboses. 
There may be unknown genetic risk factors involved in 
immune response genes or coagulation that predispose certain 
individuals to complications of catheter use. Further studies 
may identify such factors. Currently, concern for the risks 
of central catheters has led to a number of treatment options 
that may compromise the optimal treatment of infusion 
every other day.
Are all currently available 
recombinant factor VIII products 
interchangeable?
This question is a difficult one to answer, and the clear 
evidence-based response is that it cannot be answered 
fully until there are prospective randomized clinical trials 
comparing treatment using product A with treatment using 
product B. Such clinical trials are unlikely to happen, in 
part because such trials would be extraordinarily expensive. 
After that disclaimer, there are some differences considered 
important by some clinicians. Recombinant factor VIII 
products are divided subjectively into 4 groups. The first 
three groups are defined by amounts of human plasma-
derived protein contained in the final factor VIII product, and 
are generally listed as first-, second-, and third-generation 
recombinant factor VIII products. The first generation 
products used human albumin in the media to grow the 
cell lines that produced the recombinant factor VIII. Since 
factor VIII is a relatively unstable molecule albumin was 
used to help stabilize the factor VIII in the final product. 
The second generation products used less albumin at each 
stage of development and production.64 The third generation 
products used essentially no human plasma-derived proteins 
in the development or production stages.65 All three genera-
tions of recombinant factor VIII are based on the full length 
gene with very minor differences in sequences that are not 
significant. Two different mammalian cell lines are used to 
produce these three generations of recombinant factor VIII, 
leading to measurable differences in the glycosylation of the 
factor VIII protein that is infused. Since factor VIII is a highly 
glycosylated molecule there were intensive studies to detect 
clinically significant differences between the molecules.66 
None was identified.
For the three generations of full length recombinant 
factor VIII there are many studies in patients with hemo-
philia A, but none that directly compares one generation 
with another product or generation. Given that lack of 
direct comparison, however, one can attempt to compare 
the results of the various clinical studies, and, given the 
lack of direct comparison data, it appears that there is no 
detectable difference in effective half-life, in efficacy to 
treat bleeds, either spontaneous or traumatic, in efficacy 
during surgery, in inhibitor formation in children who 
have never been previously treated with factor VIII 
products, in inhibitor formation in individuals who have 
been previously treated with other factor VIII products, 
or in complications during infusions. After over a decade 
of experience with these three generations of recombi-
nant factor VIII products in hemophilia A, the choice of 
which product to use is driven by ease of administration, 
insurance company reimbursement decisions, perceived 
concerns regarding the theoretical potential of viral trans-
mission,67 and social issues. Most clinicians regard these 
products as essentially equivalent, and allow the patient Therapeutics and Clinical Risk Management 2009:5 398
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and/or his family or his insurance to decide which of these 
products to infuse.
The fourth group of recombinant factor VIII is defined 
based on its lacking the B-domain of  the factor VIII molecule.68 
The B domain is the central portion of the full length protein 
that is removed during synthesis in normal liver cells, and 
constitutes nearly one third of the molecular weight of the 
factor VIII molecule. Interestingly, the B domain is relatively 
highly conserved through evolution, and yet no physiological 
function has been identified for the B domain. Presumably, it 
represents an example of the lack of efficiency of evolution, 
in that evolutionary pressures apply only to protein sequences 
that carry survival disadvantages, and even large protein 
domains can survive through evolution, as long as they do 
not convey disadvantageous characteristics.
Interestingly, the B-domainless recombinant FVIII 
has not enjoyed the commercial success of the full length 
recombinant factor VIII products. Perhaps part of the lack 
of acceptance in the hemophilia community was reflected 
in questions regarding efficacy. Initially Gruppo et al raised 
questions regarding its clinical efficacy, despite uncontrolled 
cohort clinical studies essentially equivalent to similar 
studies using the full length plasma-derived or full length 
recombinant factor VIII.69 In a meta-analysis of 13 such 
clinical studies they reported finding reduced hemostatic 
efficacy during prophylaxis and shortened half-life of B 
domain deleted recombinant factor VIII compared with 
full length factor VIII.70 As they stated, clearly such meta-
analyses lack the power of studies that directly compare the 
products. Such direct comparison studies were performed 
using plasma-derived factor VIII (Hemophil M) and sepa-
rately using full length recombinant factor VIII (Advate®; 
Baxter Healthcare). The direct pharmacokinetic comparisons 
showed that the factor VIII products are bioequivalent to 
each other.68,71
Current treatment of hemophilia 
adults with recombinant factor 
VIII – how much is optimally safe?
Almost two generations of patients with severe hemophilia A 
have experienced the benefits of the widely available factor 
VIII preparations. After the crises of two blood product 
transmitted viral infections, the hemophilia community 
now has many senior citizens with severe hemophilia A. 
This marked increase in adults with severe hemophilia A 
is a blessing from the medical progress of the last century, 
but now the community is facing for the first time large 
numbers of hemophilia patients with concomitant medical 
problems that may interact with hemophilia in strange 
and unpredictable ways.72 Establishing the data to support 
evidence based clinical decisions for these patients will be a 
challenge.73 There is some suggestion that the risk of spon-
taneous intracranial hemorrhage in individuals with severe 
hemophilia A, highest in the neonatal period, may increase 
again in older patients due to other risk factors such as age, 
hypertension, and arteriosclerosis. As another example, 
consider that myocardial infarction results primarily from 
acute thrombosis of coronary arteries. Thus, does severe 
hemophilia A reduce the risk of developing atherosclerosis, 
and/or of suffering from myocardial infarction? Tuinenburg 
et al recently published a review that concluded hemophilia 
was associated with a relatively lower risk of cardiovas-
cular disease, but that the incidence was increasing as the 
population with hemophilia ages.74 However, in populations 
with normal coagulation, elevated factor VIII activity is 
associated with increased risk of cardiovascular events, 
including myocardial infarction.75 Since current treatment 
for hemophilia A uses episodic infusion of factor VIII, is 
there a risk associated with infusions that achieve peak 
factor VIII activity concentrations of greater than 100%? 
Do adults have different risks from these prophylactic 
infusions compared to children without co-morbidities? 
A different set of questions revolve around the use of 
recombinant factor VIII versus plasma-derived factor VIII 
preparations in adults. Elevated von Willebrand protein 
is also an independent risk factor for cardiovascular and 
thrombotic disease.75 Is there a risk associated with the use 
of von Willebrand protein containing plasma-derived factor 
VIII preparations in adults with concomitant cardiovascular 
disease?76 Will a different set of clinical guidelines for 
infusion therapy need to be developed for older adults with 
severe hemophilia A? Such questions will be answered only 
through clinical investigation.
Current promising developments  
in therapy with recombinant  
factor VIII
Current therapy of hemophilia A has achieved essentially 
normal life expectancy for boys born today with severe 
hemophilia A. Thus, any new developments in treatment 
will require significant concerns for safety, both immediate 
and in the long term. These safety concerns will justifiably 
slow the development of novel treatments for severe hemo-
philia A.77 In active clinical research are two approaches Therapeutics and Clinical Risk Management 2009:5 399
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that illustrate alternative strategies for improved hemophilia 
treatment.
A number of research groups seek to prolong the 
biological efficacy of the infused recombinant factor VIII. 
One such promising development is in advanced stages of 
clinical trial.78,89 In this approach, the recombinant factor VIII 
molecule is non-covalently attached to a pegylated liposome 
molecule prior to infusion. In two phase I clinical trials this 
preparation was shown to be safe for at least one infusion 
in patients with severe hemophilia A, and also to prolong 
the interval free of spontaneous bleeding after prophylactic 
infusion.79–82 Using this new formulation of recombinant 
factor VIII, there is a pivotal non-inferiority trial currently 
underway with enrollment expected to be completed in the 
third quarter of 2009. Each subject will be followed for one 
year, with randomization to compare clinical efficacy using 
standard recombinant factor VIII infused three times each 
week, with efficacy using the pegylated liposomal factor VIII 
infused once a week. This clinical trial should provide results 
in 2010. Other approaches not yet in clinical trial include 
genetic modifications of factor VIII to extend the half-life 
after infusion, to use gene therapy approaches to express 
normal factor VIII, and genetic modifications to extend the 
half life of factor VII to allow effective coagulation in the 
absence of normal factor VIII.77,83–85
Particularly intriguing may be the approach to modify 
the balance of coagulation so that spontaneous bleeding 
occurs much less frequently. In vivo, coagulation requires the 
reaction complex of factor IX and its cofactor factor VIII to 
activate factor X rapidly, in part because tissue factor pathway 
inhibitor limits the rate of the reaction of factor VIIa to activate 
factor X. One of the mechanisms by which NovoSeven treats 
bleeding in severe hemophilia A patients is believed to be 
that the limiting activity of tissue factor pathway inhibitor 
on the reaction of factor VIIa to activate factor X directly 
is overwhelmed by large concentrations of factor VIIa, 
thus essentially bypassing the need for any activity of the 
coagulation complex of factor IX/factor VIII. Using in vitro 
models of coagulation, it has been demonstrated that inhibi-
tion of the limiting activity of tissue factor pathway inhibitor 
allows coagulation to proceed as rapidly as addition of large 
concentrations of activated factor VIIa, as rapidly as severe 
hemophilia A plasma treated with factor VIII, and as rapidly 
as normal plasma or whole blood.86 An oral compound that 
inhibited tissue factor pathway inhibitor might allow an indi-
vidual with severe hemophilia A to avoid any spontaneous 
bleeding and thus, to avoid the need for intravenous infusions 
of factor VIII entirely except for bleeding associated with 
trauma or surgery. Clinical trials will be needed to evaluate 
the efficacy and safety of such inhibitors.
Thoughts on current controversies 
in optimal treatment of severe 
hemophilia A with recombinant 
factor VIII
Within the hemophilia community there are many different 
opinions regarding optimal treatment for hemophilia A, 
reflecting the tumultuous past 3 decades of exciting new 
developments in treatment and the experiences of two 
devastating viral epidemics transmitted through promising 
new treatment products. The community needs more data 
to provide evidence to support treatment guidelines.87,88 
Three controversies will be addressed here, partly in hopes 
of encouraging the community to consider participation in 
prospective clinical trials.
Spontaneous intracranial bleeding is a frightening 
complication of severe hemophilia A. It occurs essentially 
only when the factor VIII activity is less than 2%, and it occurs 
primarily in children under the age of 4, in whom the use of 
central venous access devices is associated with higher risk 
of serious infectious or thrombotic complications. Thus, some 
clinicians eschew the use of vascular access in these children 
in fear of the complications, while other clinicians embrace 
their use in order to prevent intracranial hemorrhage and any 
neurological damage. Multicenter prospective trials are needed 
to define the balancing point where benefits outweigh the risks, 
and which procedures are associated with optimal outcomes.
In the hemophilia community over the past few years, 
current treatment schedules with recombinant factor VIII, 
with the proven efficacy to prevent bleeding, and with the 
tremendous safety record, have led to a shift in the paradigm 
for treatment of severe hemophilia A. Previous studies have 
focused on preventing joint damage. The new paradigm 
is to prevent any spontaneous bleeding at all. This shift 
in thinking is analogous to earlier shifts in medicine with 
other disorders, such as treating hypertension rather than 
simply trying to prevent strokes, or such as treating blood 
sugar in diabetes rather than simply trying to prevent kidney 
damage. The defect in hemophilia A is a lack of factor VIII 
coagulation activity, and the goal of treatment should be 
replacement of factor VIII activity and prevention of any 
spontaneous bleeding. This new shift in considering how to 
treat severe hemophilia A is reflected in the US FDA’s recent 
decision to grant an indication for use in prophylaxis to one 
of the recombinant factor VIII products currently available. Therapeutics and Clinical Risk Management 2009:5 400
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This decision was based in part on a prospective randomized 
clinical trial that compared two treatment schedules using 
recombinant factor VIII for severe hemophilia A.30 This 
clinical trial compared prophylaxis treatment with on demand 
treatment in children, and clearly demonstrated in this young 
population the superiority of prophylaxis treatment with 
recombinant factor VIII. Other trials will need to address 
among other considerations, questions of appropriate dosing 
of factor VIII, whether plasma-derived factor VIII or other 
recombinant factor VIII products convey similar efficacy, 
and whether similar beneficial outcomes occur in adults with 
severe hemophilia A.
The third area for consideration reflects that for the past 
two decades the hemophilia community has pushed diligently 
for factor VIII that was safer, with safety defined as higher 
purity factor VIII protein with no associated human plasma-
derived products. Now, the question is being refocused to: 
how safe is this definition of safety?1,2 No plasma-derived 
factor VIII preparation has transmitted any documented viral 
illness since 1990. The safety concern now revolves around 
fear of transmission of prions, or perhaps fear of “the next” 
as yet unidentified “virus”, sometimes loosely named “TNV.” 
Are these concerns still rational, in view of the two decades 
long safety record for all plasma-derived factor VIII prepara-
tions and the documented absence of known transmission of 
prion disease by any factor VIII preparation?67 If the alterna-
tive risks were only theoretical or even perhaps only financial, 
then the concerns might be rational. However, in view of the 
accumulating evidence that high purity factor VIII products 
lacking von Willebrand protein and recombinant factor VIII 
may be associated with increased risk of inhibitor formation, 
the new question is which risk is greater for the hemophilia 
community? Thoughtful clinicians disagree on these issues, 
based on their personal experiences and in the absence of 
data supported conclusions based on prospective compara-
tive clinical trials. Some clinicians use only recombinant 
factor VIII, so that children never exposed to blood products 
remain never exposed, because of fear of prions or TNV. 
Other clinicians use only plasma-derived von Willebrand 
protein containing factor VIII preparations because they are 
convinced that inhibitor development is significantly reduced, 
and they apparently view the concern of viral transmission 
as much less significant for their patients.
Will a way forward be found? Given the tremendous 
progress in hemophilia over the past 40 years, it is likely 
that the hemophilia community will indeed find a new 
development. Perhaps prospective clinical trials will be 
started to address the question directly. Perhaps recombinant 
von Willebrand protein will be developed and its addition 
to recombinant factor VIII will be tested in prospective 
randomized clinical trials. Perhaps the pegylated liposome 
factor VIII product currently in phase 3 clinical trial will 
prove further useful as a carrier molecule for factor VIII, 
and the risk of inhibitor formation will be as low as the 
heralded low risk for plasma-derived von Willebrand protein 
containing factor VIII products. Hopefully, the hemophilia 
community will participate actively in the clinical trials 
needed to address these questions. Of the many possibilities 
it is certain only that the future will be interesting.
Summary
The hemophilia community has achieved a remarkable goal 
for treatment of severe hemophilia A: normal life expectancy 
for a previously life threatening disease. Now, the challenges 
will be to improve further the quality of the life of an indi-
vidual with severe hemophilia A, and to reduce the burden of 
current treatment strategies on families and medical resources. 
Promising new recombinant factor VIII products are in 
advanced stages of clinical trials, and studies are underway 
to address how to optimally use current resources to improve 
quality of life for individuals with severe hemophilia A.
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